The clinical trial, sponsored by Jian-Kun Hu at West China Hospital, aims to evaluate the safety and efficacy of EpCAM-targeted CAR-T cell therapy for advanced gastric cancer with peritoneal metastasis. Given the high incidence and mortality rates of gastric cancer, particularly in China, this trial addresses a significant unmet medical need. If successful, the therapy could provide a novel treatment option in a market with limited effective therapies for this patient population. The competitive landscape includes traditional chemotherapy and emerging immunotherapies, necessitating thorough diligence on regulatory pathways and potential partnerships for commercialization.